Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (371-380 of 635) with videos related to

Pageof 64
Sort By:
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
Journal of Cardiac Failure|April 6, 2024
Real-world walking behaviors are associated with early-stage heart failure: a Project Baseline Health StudySooyoon Shin, Nathan Kowahl, Taylor Hansen, et al.
Heart (British Cardiac Society)|April 7, 2017
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromesJoakim Alfredsson, Benjamin Neely, Megan L Neely, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
Circulation. Cardiovascular Interventions|July 13, 2021
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID TrialWilliam R Hiatt, Connie N Hess, Marc P Bonaca, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
The American Journal of Medicine|January 23, 2016
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery DiseaseRenato D Lopes, Meena Rao, DaJuanicia N Simon, et al.
Journal of the American College of Cardiology|November 28, 2015
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF TrialMatthew W Sherwood, Christopher C Nessel, Anne S Hellkamp, et al.
Circulation. Cardiovascular Quality and Outcomes|July 4, 2020
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID TrialChandler A Long, Hillary Mulder, F Gerry R Fowkes, et al.
American Heart Journal|June 22, 2015
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registrySean D Pokorney, DaJuanicia N Simon, Laine Thomas, et al.
Pageof 64

Showing results (371-380 of 635) with videos related to

Sort By:
Pageof 64
European Heart Journal. Acute Cardiovascular Care|March 15, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trialClaes Held, Pierluigi Tricoci, Zhen Huang, et al.
Journal of Cardiac Failure|April 6, 2024
Real-world walking behaviors are associated with early-stage heart failure: a Project Baseline Health StudySooyoon Shin, Nathan Kowahl, Taylor Hansen, et al.
Heart (British Cardiac Society)|April 7, 2017
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromesJoakim Alfredsson, Benjamin Neely, Megan L Neely, et al.
Journal of the American Heart Association|December 12, 2018
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER TrialLeo Ungar, Robert M Clare, Fatima Rodriguez, et al.
Circulation. Cardiovascular Interventions|July 13, 2021
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID TrialWilliam R Hiatt, Connie N Hess, Marc P Bonaca, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.
The American Journal of Medicine|January 23, 2016
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery DiseaseRenato D Lopes, Meena Rao, DaJuanicia N Simon, et al.
Journal of the American College of Cardiology|November 28, 2015
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF TrialMatthew W Sherwood, Christopher C Nessel, Anne S Hellkamp, et al.
Circulation. Cardiovascular Quality and Outcomes|July 4, 2020
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID TrialChandler A Long, Hillary Mulder, F Gerry R Fowkes, et al.
American Heart Journal|June 22, 2015
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registrySean D Pokorney, DaJuanicia N Simon, Laine Thomas, et al.
Pageof 64